Increased paclitaxel resistance in recurrent epithelial ovarian cancer: analysis of metachronous tumors


Whether or not ovarian cancer exhibits tumor heterogeneity before and after chemotherapy, demonstrated in an in vitro drug resistance assay, seems to remain controversial [1–4]. In the largest analysis of an unselected population with ovarian cancer, there was no significant difference in the proportion of extreme drug resistance (EDR) between primary and… (More)
DOI: 10.1007/s10147-010-0032-2


2 Figures and Tables

Slides referencing similar topics